Oncolytic adenoviruses for treatment of brain tumours

Bibliography

• DAVIS FG, FREELS S, GRUTSCH J, BARLAS S, BREM S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neumsurg. (1998) 88:1–10.
   PubMed Web of Science ®Google Scholar
• RAINOV NG: A Phase III clinical evaluation of herpes simplex virusType 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene flier. (2000) 11:2389–2401.
   Google Scholar
• •The first and single performed Phase III trial in cancer gene therapy; retrovirus mediated enzyme prodrug therapy.
   Google Scholar
• ALEMANY R, GOMEZ-MANZANO C,BALAGUE C et al: Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp. Cell Res. (1999) 252:1–12.
   PubMed Web of Science ®Google Scholar
• •Thorough overview.
   Google Scholar
• MARKERT JM, GILLESPIE GY, WEICHSELBAUM RR, ROIZMAN B, WHITLEY RJ: Genetically engineered HSV in the treatment of glioma: a review. Rev. Med. Viral. (2000) 10:17–30.
   PubMed Web of Science ®Google Scholar
• GROMEIER M, LACHMANN S, ROSENFELD MR, GUTIN PH, WIMMER E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA (2000) 97:6803–6808.
   PubMed Web of Science ®Google Scholar
• COFFEY MC, STRONG JE, FORSYTH PA, LEE PW: Reovirus therapy of tumors with activated Ras pathway. Science(1998) 282:1332–1334.
   PubMed Web of Science ®Google Scholar
• SOUTHAM CM: present status of oncolytic virus studies. NY Acad. Sci. (1960) 22:656–673.
   Google Scholar
• •Review of an impressive number of oncolytic virus studies in humans performed almost half a century ago.
   Google Scholar
• TEODORO JG, BRANTON PE:Regulation of apoptosis by viral gene products.Viral. (1997) 71:1739–1746.
   Google Scholar
• •Complete review of viral oncolytic action.
   Google Scholar
• ZHANG Y, SCHNEIDER RJ: Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeratin network. J. Vim/. (1994) 68:2544–2555.
   Web of Science ®Google Scholar
• BRAITHWAITE AW, RUSSELL IA: Induction of cell death by adenoviruses. Apoptosis. (2001) 6:359–370.
   PubMed Web of Science ®Google Scholar
• SHTRICHMAN R, KLEINBERGER T: Adenovirus Type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J. Virol (1998) 72:2975–2982.
   PubMed Web of Science ®Google Scholar
• MARCELLUS RC, LAVOIE JN, BOIVIN D et al.: The early region 4 orf4 protein of human adenovirus Type 5 induces p53- independent cell death byapoptosis.Virol (1998) 72:7144–7153.
   Web of Science ®Google Scholar
• TOLLEFSON AE, SCARIA A, HERMISTON TW et al.: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol (1996) 70:2296–2306.
   Google Scholar
• YANG Y, SU Q, WILSON JM: Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol (1996) 70:7209–7212.
   PubMed Web of Science ®Google Scholar
• YANG Y, JOOSS KU, SU Q, ERTL HC, WILSON JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene The]: (1996) 3:137–144.
   PubMed Web of Science ®Google Scholar
• WORGALL S, WOLFF G, FALCK-PEDERSEN E, CRYSTAL RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Then (1997) 8:37–44.
   PubMed Web of Science ®Google Scholar
• GINSBERG HS, PRINCE GA: The molecular basis of adenovirus pathogenesis. Infect. Agents Dis. (1994) 3:1–8.
   PubMedGoogle Scholar
• NAKAGAWA I, MURAKAMI M, IJIMA K et al.: Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. Hum. Gene Then (1998) 9:1739–1745.
   PubMed Web of Science ®Google Scholar
• IKEDA K, ICHIKAWA T,WAKIMOTO H et al: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. (1999) 5:881–887.
   PubMed Web of Science ®Google Scholar
• GEUTSKENS SB, VAN DER EB MM, PLOMP AC et al.: Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Thec (2000) 7:1410–1416.
   Google Scholar
• LIEBER A, HE CY, MEUSE Let al.: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Virol (1997) 71:8798–8807.
   Google Scholar
• •Beneficial effect of immune response regarding oncolytic effect.
   Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373–376.
   PubMed Web of Science ®Google Scholar
• •First description of conditionally replicating adenovirus, based on genomic deletion, p53 dependant.
   Google Scholar
• RIES SJ, BRANDTS CH, CHUNG AS et al: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat. Med. (2000) 6:1128–1133.
   PubMed Web of Science ®Google Scholar
• HEISE CC, WILLIAMS AM, XUE S, PROPST M, KIRN DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. (1999) 59:2623–2628.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY et al.: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559–2563.
   PubMed Web of Science ®Google Scholar
• KIRN D: Clinical research results with d11520 (Onyx-015), a replication- selective adenovirus for the treatment of cancer: what have we learned? Gene Then (2001) 8:89–98.
   PubMed Web of Science ®Google Scholar
• FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al: A mutant oncolytic adenovirus targeting the Rb pathway produces anti- glioma effect in vivo. Oncogene (2000) 19:2–12.
   PubMed Web of Science ®Google Scholar
• •Description of CRAd based on mutation in Rb pathway.
   Google Scholar
• HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus ElA mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. (2000) 6:1134–1139.
   PubMed Web of Science ®Google Scholar
• JOHNSON L, SHEN A, BOYLE L et al: Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1:325–337.
   PubMed Web of Science ®Google Scholar
• MORELLI AE, LARREGINA AT, SMITH-ARICA J et al.: Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducingmolecule Fas ligand to predetermined braincell types, and abolish peripheral liver toxicity. J. Gen. Virol (1999)80(Pt 3):571–583.
   PubMedGoogle Scholar
• KURIHARA H, ZAMA A, TAMURA Met al.: Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Thec (2000) 7:686–693.
   Google Scholar
• MIYAO Y, SHIMIZU K, TAMURA M et al.: Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. fpn. J. Cancer Res. (1997) 88:678–686.
   PubMedGoogle Scholar
• SHINOURA N, SAITO K, YOSHIDA Y et al.: Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas [In Process Citation]. Cancer Gene Then (2000) 7:739–748.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-ALCOCEBA R, PIHALJA M, WICHA MS, CLARKE MF: A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of El a-deleted adenoviral vectors. Hum. Gene Then (2000) 11:2009–2024.
   PubMed Web of Science ®Google Scholar
• HALLENBECK PL, CHANG YN, HAY C et al.: A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Thec (1999) 10:1721–1733.
   PubMed Web of Science ®Google Scholar
• KRASNYKH VN, DOUGLAS JT, VAN BEUSECHEM VW: Genetic targeting of adenoviral vectors. Ma Then (2000) 1:391–405.
   PubMed Web of Science ®Google Scholar
• ••Description of all targeting moieties.
   Google Scholar
• MILLER CR, BUCHSBAUM DJ, REYNOLDS PN et al.: Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. (1998) 58:5738–5748.
   PubMed Web of Science ®Google Scholar
• HAISMA HJ, GRILL J, CURIEL DT et al.: Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. (2000) 7:901–904.
   PubMed Web of Science ®Google Scholar
• VAN BEUSECHEM VW, GRILL J, MASTENBROEK DC et al.: Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors withnative tropism abolished. J. Vim/. (2002) 76:2753–2762.
   Web of Science ®Google Scholar
• GRILL J, VAN BEUSECHEM VW, VAN DER VALK P et al.: Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. (2001) 7:641–650.
   Google Scholar
• SHINOURA N, YOSHIDA Y, TSUNODA R et al.: Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. (1999) 59:3411–3416.
   PubMed Web of Science ®Google Scholar
• •First report of improved action of a CRAd when combined with transductional targeting.
   Google Scholar
• LAMFERS MLM, GRILL J,DIRVEN CMF et al.: Potential of the conditionally replicative adenovirus Ad5-424RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. (2002) 62(20):5736–5742.
   Google Scholar
• SILBERGELD DL, CHICOINE MR: Isolation and characterization of human malignant glioma cells from histologically normal brain. Neurosurg. (1997) 86:525–531.
   Web of Science ®Google Scholar
• •On migratory capacity of malignant glioma cells.
   Google Scholar
• PUUMALAINEN AM, VAPALAHTI M, AGRAWAL RS et al.: Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Met: (1998) 9:1769–1774.
   Google Scholar
• YU X, LIU Z, TIAN Z et al.: Stereotactic biopsy for intracranial space-occupying lesions: clinical analysis of 550 cases. Stereotact. Funct. Neurosurg. (2000) 75:103–108.
   PubMed Web of Science ®Google Scholar
• BOBO RH, LASKE DW, AKBASAK A et al.: Convection-enhanced delivery of macromolecules in the brain. Proc. Nati Acad. Sci. USA (1994) 91:2076–2080.
   PubMed Web of Science ®Google Scholar
• ••Describes new method of delivery of largevolumes with wide distribution in the brain, convection enhanced delivery.
   Google Scholar
• PRABHU SS, BROADDUS WC, GILLIES GT et al: Distribution of macromolecular dyes in brain using positive pressure infusion: a model for direct controlled delivery of therapeutic agents. Surg. Neurol (1998) 50:367–375.
   PubMed Web of Science ®Google Scholar
• LASKE DW, MORRISON PF, LIEBERMAN DM et al: Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging.Neurosurg. (1997) 87:586–594.
   Web of Science ®Google Scholar
• BRUCE JN, FALAVIGNA A, JOHNSON JP et al.: Intracerebral cl ysis in a rat glioma model. Neurosurgery(2000) 46:683–691.
   PubMed Web of Science ®Google Scholar
• KROLL RA, PAGEL MA, MULDOON LL, ROMAN-GOLDSTEIN S, NEUWELT EA: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 38:746–752.
   PubMed Web of Science ®Google Scholar
• LASKE DW, YOULE RJ, OLDFIELD EH: Tumor regression with regional distribution of the targeted toxin TF- CRIVI107 in patients with malignant brain tumors. Nat. Med. (1997) 3:1362–1368.
   PubMed Web of Science ®Google Scholar
• •Detailed clinical study showing feasibility of convection enhanced delivery.
   Google Scholar
• CUNNINGHAM J, OIWA Y, NAGY D et al.: Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant. (2000) 9:585–594.
   PubMed Web of Science ®Google Scholar
• MASTAKOV MY, BAER K, XU R, FITZSIMONS H, DURING MJ: Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol. Ther. (2001) 3:225–232.
   PubMed Web of Science ®Google Scholar
• MASTAKOV MY, BAER K, KOTIN RM, DURING MJ: Recombinant Adeno-associated Virus Serotypes 2- and 5-Mediated Gene Transfer in the Mammalian Brain: Quantitative Analysis of Heparin Co-infusion. Mol. Ther. (2002) 5:371–380.
   PubMed Web of Science ®Google Scholar
• NGUYEN JB, SANCHEZ-PERNAUTE R, CUNNINGHAM J, BANKIEWICZ KS: Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport (2001) 12: 1961-1964.
   Google Scholar
• SCHELLINGERHOUT D,BOGDANOV A, JR., MARECOS E et al: Mapping the in vivo distribution of herpes simplex virions. Hum. Gene Met: (1998) 9:1543–1549.
   Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Titer: (2001) 8:746–759.
   Web of Science ®Google Scholar
• HABIB NA, SARRAF CE, MITRY RR et al.: E1B-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Titer. (2001)12:219–226.
   PubMed Web of Science ®Google Scholar
• MULDOON LL, NILAVER G,KROLL RA et al.: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. Pathol. (1995) 147:1840–1851.
   Google Scholar
• RAINOV NG, DOBBERSTEIN KU, HEIDECKE V et al.: Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Met: (1998) 5:158–162.
   PubMed Web of Science ®Google Scholar
• •First report on feasibility of brain tumour transduction by way of systemic delivery of vector.
   Google Scholar
• RAINOV NG, IKEDA K, QURESHI NH et al.: Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum. Gene Met: (1999) 10:311–318.
   Google Scholar
• ABET, WAKIMOTO H, BOOKSTEIN R et al.: Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Met: (2002) 9:228–235.
   PubMed Web of Science ®Google Scholar
• HEISE C, LEMMON M, KIRN D: Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin. Cancer Res. (2000) 6:4908–4914.
   PubMedGoogle Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3:639–645.
   PubMed Web of Science ®Google Scholar
• KHURI FR, NEMUNAITIS J, GANLY I et al.: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6:879–885.
   PubMed Web of Science ®Google Scholar
• •Impressive results of CRAd therapy combined with chemotherapy.
   Google Scholar
• YU DC, CHEN Y, DILLEY J et al:Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. (2001) 61:517–525.
   PubMed Web of Science ®Google Scholar
• RAINOV NG, FELS C, DROEGE JW et al.: Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther. (2001) 8:662–668.
   PubMed Web of Science ®Google Scholar
• ROGULSKI KR, WING MS, PAIELLI DL et al.: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther. (2000) 11:67–76.
   PubMed Web of Science ®Google Scholar
• DEWEESE TL, VAN DER PH, LI S et al:A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. (2001) 61:7464–7672.
   PubMed Web of Science ®Google Scholar
• CHEN Y, DEWEESE T, DILLEY Jet al.: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. (2001) 61:5453–5460.
   Google Scholar
• GEOERGER B, GRILL J, OPOLON P et at.: ONYX-015, an E1B-55 kD deleted adenovirus, potentiates radiation therapy in human malignant glioma xenografts. Proc. Am. Soc. Clin. Oncol (2001)20:53a. Abstract #209.
   Google Scholar
• NANDA D, VOGELS R, HAVENGA M et al.: Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. (2001) 61:8743–8750.
   PubMed Web of Science ®Google Scholar
• GRILL J, LAMFERS MLM, VAN BEUSECHEM VW et al: The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication andpenetration in human tumours M vitra Mot. Ther. (2002) 6(5):609–614.
   Google Scholar
• WILDNER 0, BLAESE PM,MORRIS IC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. (1999) 59:410–413.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, MORRIS IC,VAHANIAN NN et al.: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. (1999) 6:57–62.
   Google Scholar
• MORRIS IC, RAMSEY WI, WILDNER 0 et al.: A Phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum. Gene Ther. (2000) 11:487–503.
   Google Scholar
• MORRIS IC, WILDNER 0: Therapy ofhead and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol. Ther. (2000) 1:56–62.
   PubMed Web of Science ®Google Scholar
• FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. (1998) 9:1323–1333.
   PubMed Web of Science ®Google Scholar
• •Shows feasibility of multimodal combination therapy.
   Google Scholar
• LAMBRIGHT ES, AMIN K, WIEWRODT R et al.: Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. (2001) 8:946–953.
   PubMed Web of Science ®Google Scholar
• KATABI M, YUAN S, CHAN H, GALIPEAU J, BATIST G: The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus Type 5 early region 4. Mol. Ther. (2002) 5:170–176.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, MORRIS IC: The role ofthe ElB 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res. (2000) 60:4167–4174.
   PubMed Web of Science ®Google Scholar
• KRUYT FA, CURIEL DT: Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. (2002) 13:485–495.
   PubMed Web of Science ®Google Scholar
• •Review indicating future directions.
   Google Scholar
• MARKERT IM, MEDLOCK MD, RABKIN SD et al: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial [see comments]. Gene Ther. (2000) 7:867–874.
   PubMed Web of Science ®Google Scholar
• RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma [see comments]. Gene Ther. (2000) 7:859–866.
   Google Scholar
• WILD-BODE C, WELLER M, RIMNER A, DICHGANS J, WICK W: Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. (2001) 61:2744–2750.
   PubMed Web of Science ®Google Scholar
• ABOODY KS, BROWN A, RAINOV NG et al.: From the cover: neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. NatL Acad. Sci. USA (2000) 97:12846–12851.
   PubMed Web of Science ®Google Scholar
• ••Stem cells as a new tool to reach infiltratedtumour cells.
   Google Scholar
• GEOERGER B, GRILL J, OPOLON P et al.: Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. (2002) 62:764–772.
   PubMed Web of Science ®Google Scholar
• GOMEZ-MANZANO C, LEMOINE MG, HUM et al.: Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int. J. Oncol (2001) 19:359–365.
   PubMed Web of Science ®Google Scholar
• SHINOURA N, SAKURAI S, ASAI A, KIRINO T, HAMADA H: Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells. fpn. J. Cancer Res. (2001) 92:467–474.
   PubMedGoogle Scholar
• LAMMERING G, VALERIE K, LIN PS et al.: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res. (2001) 7:682–690.
   PubMed Web of Science ®Google Scholar
• LANG FF, YUNG WK, RAJU U et al: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.Neurosurg. (1998) 89:125–132.
   Web of Science ®Google Scholar